Código QR

Unanswered questions on the use of biologics in pediatric asthma

The emergence of biologic therapies for the management of asthma has been a revolutionary change in our capacity to manage this disease.Since the launch of omalizumab, several other biologics have been marketed or are close to being marketed, suggesting that a plethora of monoclonal antibodies can b...

Descripción completa

Guardado en:
Autores principales: Antonio Nieto, MD, PhD, Zeinab A. El-Sayed, MD, PhD, René Maximiliano Gómez, PhD, Elham Hossny, MD, PhD, Wang Jiu-Yao, MD, DPhil, Ömer Kalayci, MD, Mário Morais-Almeida, Wanda Phipatanakul, MD, Paulo Marcio Pitrez, MD, César Fireth Pozo Beltrán, MD, Paraskevi Xepapadaki, MD, Nikolaos G. Papadopoulos, MD, PhD
Formato: Artigo
Lenguaje:Inglês
Publicado: Elsevier 2023-11-01
Colección:World Allergy Organization Journal
Materias:
Severe childhood asthma
Biologics
Omalizumab
Mepolizumab
Benralizumab
Dupilumab
Acceso en línea:http://www.sciencedirect.com/science/article/pii/S1939455123000972
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares